Zentalis Pharmaceuticals Llc
$ 4.64
-7.57%
17 Apr - close price
- Market Cap 329,120,000 USD
- Current Price $ 4.64
- High / Low $ 5.23 / 4.38
- Stock P/E N/A
- Book Value 3.13
- EPS -1.91
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.50 %
- 52 Week High 6.95
- 52 Week Low 1.13
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
Analyst Target Price
$6.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-10 | 2025-08-06 | 2025-05-05 | 2025-02-25 | 2024-11-04 | 2024-08-09 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.49 | -0.37 | -0.37 | -0.67 | -0.6138 | -0.56 | -1.24 | 0.14 | -0.93 | -0.79 | -1.85 | -1.07 |
| Estimated EPS | -0.4796 | -0.53 | -0.54 | -0.6069 | -0.6817 | -0.8708 | -0.84 | -0.77 | -0.92 | -0.91 | -1.04 | -1.02 |
| Surprise | -0.0104 | 0.16 | 0.17 | -0.0631 | 0.0679 | 0.3108 | -0.4 | 0.91 | -0.01 | 0.12 | -0.81 | -0.05 |
| Surprise Percentage | -2.1685% | 30.1887% | 31.4815% | -10.3971% | 9.9604% | 35.6913% | -47.619% | 118.1818% | -1.087% | 13.1868% | -77.8846% | -4.902% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.49 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZNTL
2026-04-17 19:40:13
Zentalis Pharmaceuticals will present preclinical data on azenosertib in triple-negative breast cancer (TNBC) and a real-world analysis of unmet needs in Cyclin E1-positive ovarian cancer at the AACR 2026 annual meeting. Preclinical studies show azenosertib combinations induce complete tumor responses in ADC-resistant TNBC models, indicating potential for pipeline expansion beyond ovarian cancer. Furthermore, real-world data confirm that Cyclin E1-positive ovarian cancer patients face significantly worse outcomes, reinforcing the need for targeted treatments like azenosertib.
2026-04-17 19:40:13
Zentalis Pharmaceuticals announced it will present preclinical data on its WEE1 inhibitor, azenosertib, in combination therapies for triple-negative breast cancer (TNBC) and a real-world analysis highlighting the unmet need in Cyclin E1-positive ovarian cancer at the 2026 AACR Annual Meeting. The preclinical data suggest azenosertib combinations show encouraging activity in ADC-resistant TNBC models, while real-world data confirm Cyclin E1-positive ovarian cancer patients face significantly worse outcomes regardless of gene amplification status. These findings support the potential for azenosertib as a targeted treatment for both cancer types.
2026-04-17 19:39:52
Zentalis Pharmaceuticals (Nasdaq: ZNTL) presented new preclinical data for its WEE1 inhibitor, azenosertib, at AACR 2026, showing significant tumor growth inhibition in triple-negative breast cancer (TNBC) models, especially in combination therapies. Additionally, real-world data revealed that Cyclin E1-positive ovarian cancer patients experience a poorer prognosis and shorter time to next treatment, underscoring this population as a key target for Zentalis’s late-stage azenosertib studies. The findings suggest azenosertib’s potential to address unmet medical needs in both ADC-resistant TNBC and Cyclin E1-positive platinum-resistant ovarian cancer.
2026-04-14 00:09:46
Zentalis Pharmaceuticals (NASDAQ:ZNTL) has received an average "Hold" rating from seven brokerages, with an average 12-month price target of $5.83. Insider Vincent Vultaggio sold shares, but institutional investors significantly increased their stakes. The company's stock trades within a 1-year range of $1.09-$6.95, has a market cap of approximately $469 million, and reported a recent quarterly loss per share of $0.49.
2026-04-13 00:40:23
Zentalis Pharmaceuticals (ZNTL) has gained investor attention following the selection of an optimal monotherapy dose for azenosertib in platinum-resistant ovarian cancer, leading to significant recent share price increases. Despite these gains, its valuation appears inexpensive on simple checks, with its Price to Book multiple below industry average and a Discounted Cash Flow model suggesting a much higher fair value. However, the company faces risks due to ongoing net losses and reliance on external borrowing for clinical development.
2026-04-12 08:33:00
Zentalis Pharmaceuticals Inc. (ZNTL) stock has surged by 52.47% following Guggenheim's increased price target from $6 to $10, driven by promising FDA designations and successful trial results for its ovarian cancer treatments. The company reported a narrower loss in 2025 and has extended its cash runway into late 2027, despite facing significant financial challenges. Zentalis's focus on late-stage clinical trials, particularly the WEE1 inhibitor azenosertib, positions it for potential breakthroughs and outperformance in the Biotechnology & Life Sciences sector.
